Cargando…
Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience
Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the pre...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416594/ https://www.ncbi.nlm.nih.gov/pubmed/36016112 http://dx.doi.org/10.3390/vaccines10081224 |
_version_ | 1784776516880564224 |
---|---|
author | Bloise, Silvia Marcellino, Alessia Frasacco, Beatrice Gizzone, Pietro Proietti Ciolli, Claudia Martucci, Vanessa Sanseviero, Mariateresa Del Giudice, Emanuela Ventriglia, Flavia Lubrano, Riccardo |
author_facet | Bloise, Silvia Marcellino, Alessia Frasacco, Beatrice Gizzone, Pietro Proietti Ciolli, Claudia Martucci, Vanessa Sanseviero, Mariateresa Del Giudice, Emanuela Ventriglia, Flavia Lubrano, Riccardo |
author_sort | Bloise, Silvia |
collection | PubMed |
description | Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the presence of allergic reactions or anaphylaxis, adverse events after 24–48 h, 7 and 20 days of taking the first and second doses of medications, and documented SARS-CoV-2 infection after vaccination. The information obtained was automatically linked to a spreadsheet and analyzed. Results: 569 children were enrolled. The mean age was 114 ± 4.24 months; there were 251 males in the study. The vaccine showed a favorable safety profile; no anaphylaxis or serious adverse events were reported. The most common symptoms both after the first and second dose were injection site reactions, asthenia, and headache. Injection site reactions were more frequent after the first dose (p = 0.01), while systemic symptoms were more frequent after the second dose (p = 0.022). These symptoms were more frequent in patients with comorbidities (p = 0.0159). Conclusion: Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve “herd immunity” and prevent the virus’s circulation. |
format | Online Article Text |
id | pubmed-9416594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94165942022-08-27 Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience Bloise, Silvia Marcellino, Alessia Frasacco, Beatrice Gizzone, Pietro Proietti Ciolli, Claudia Martucci, Vanessa Sanseviero, Mariateresa Del Giudice, Emanuela Ventriglia, Flavia Lubrano, Riccardo Vaccines (Basel) Article Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the presence of allergic reactions or anaphylaxis, adverse events after 24–48 h, 7 and 20 days of taking the first and second doses of medications, and documented SARS-CoV-2 infection after vaccination. The information obtained was automatically linked to a spreadsheet and analyzed. Results: 569 children were enrolled. The mean age was 114 ± 4.24 months; there were 251 males in the study. The vaccine showed a favorable safety profile; no anaphylaxis or serious adverse events were reported. The most common symptoms both after the first and second dose were injection site reactions, asthenia, and headache. Injection site reactions were more frequent after the first dose (p = 0.01), while systemic symptoms were more frequent after the second dose (p = 0.022). These symptoms were more frequent in patients with comorbidities (p = 0.0159). Conclusion: Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve “herd immunity” and prevent the virus’s circulation. MDPI 2022-07-30 /pmc/articles/PMC9416594/ /pubmed/36016112 http://dx.doi.org/10.3390/vaccines10081224 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bloise, Silvia Marcellino, Alessia Frasacco, Beatrice Gizzone, Pietro Proietti Ciolli, Claudia Martucci, Vanessa Sanseviero, Mariateresa Del Giudice, Emanuela Ventriglia, Flavia Lubrano, Riccardo Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
title | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
title_full | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
title_fullStr | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
title_full_unstemmed | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
title_short | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
title_sort | cross-sectional survey on bnt162b2 mrna covid-19 vaccine serious adverse events in children 5 to 11 years of age: a monocentric experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416594/ https://www.ncbi.nlm.nih.gov/pubmed/36016112 http://dx.doi.org/10.3390/vaccines10081224 |
work_keys_str_mv | AT bloisesilvia crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT marcellinoalessia crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT frasaccobeatrice crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT gizzonepietro crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT proietticiolliclaudia crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT martuccivanessa crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT sansevieromariateresa crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT delgiudiceemanuela crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT ventrigliaflavia crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT lubranoriccardo crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience |